Ryan White Part B Program

First Name

Member ID

Medication Assistance Program (MAP) Pre-Approval for SUNLENCA® (lenacapavir)

Last Name

RW ID (if known)

TELEPHONE: 888-311-7685 FAX: 800-848-4241 * Ramsell



Prescriptions for Sunlenca® (lenacapavir) are only available with pre-approval through the Medication Assistance Program. You can click on the name of the medication to be taken directly to the specific prescribing guidelines. Physician or pharmacy will be notified if prior-authorization is approved.

To be eligible for this pre-approval, the following criteria must be met:

- The patient is currently enrolled in MAP and eligible for MAP assistance.
- Sunlenca® (lenacapavir) is being used in combination with other antiretrovirals (ARVs).

Middle Initial

Date of Birth

- Prescriber has confirmed status of IL MAP client as a heavily treatment-experienced adult with multidrug resistant HIV-1 infection failing current ARV regimen due to resistance, intolerance, or safety considerations.
- MAP client has a current viral load greater than 200 copies per mL results must be dated within the past 6 months and documentation must be provided.

MEDICATION	STRENGTH	DOSE AND DIRECTIONS	QUANTITY / REFILLS
Sunlenca	□ 300mg tablets □ 463.5mg/1.5ml vials	Loading dose Option 1 927 mg by SQ injection (2 x 1.5ml injection) and 600 mg PO (2 x 300mg tablets) on Day 1 Then 600 mg orally (2 x 300 mg tablets) on Day 2	□ Loading dose 1 Quantity: 300 mg-4 tablet blister pack NDC 61958-3001-01 Injection dosing kit (contains 2 vials) NDC 61958-3002-01 Refills: 0
		Loading dose Option 2 600 mg PO (2 x 300mg tablets) on Day 1 600 mg PO (2 x 300 mg tablets) on Day 2 300 mg PO (1 x 300mg tablet) on Day 8 Then 927 mg by SQ injection (2 x 1.5ml injections) on Day 15	□ Loading dose 2 Quantity: 300 mg-5 tablet blister pack NDC 61958-3001-01 Injection dosing kit (contains 2 vials) 61958-3002-01 Refills: 0
			☐ Maintenance
		☐ Maintenance Dose	Quantity:
		927 mg by SQ injection (2 x 1.5ml injection) every 6 months (26 weeks) from the date of	Injection dosing kit (contains 2 vials)
		the last injection (+/- 2 weeks).	Refills: Ongoing Authorization

Most Current CD4 Count and Date	Most Recent Viral Load and Date (Provide copy of lab results)			
Who will administer the SQ medication to client?				
Who will assume responsibility for medication upon shipment arrival?				

Created: 4/7/2023 Page 1 of 2



Ryan White Part B Program

Medication Assistance Program (MAP) Pre-Approval for SUNLENCA® (lenacapavir)

TELEPHONE: 888-311-7685 FAX: 800-848-4241 * Ramsell

	Address where medication will be sent if approved?					
Provider must acknowledge the following with initials:						
I have reviewed the prescribing guidelines for use, dosing, drug interactions and missed doses for this medication.						
Patient has been cour	nseled on the high cost of treatment and is w	villing to be 100% adherent to treatment regimen.				
Date:						
To the best of my knowledge, I certify that the above is accurate and true and that this treatment is indicated, necessary and meets the guidelines for use.						
Provider Name (Print)	Provider Signa	ature				
Provider Name (Print) Clinic Name:	Provider Signa	eture Fax #				
, ,						
Clinic Name: Pharmacy Name	Phone # Pharmacy Phone #	Fax # Fax # ted below in reference to this request. Failure to				

Submit: Please fax completed application to Ramsell at **800-848-4241**. For additional information, call the Ramsell Help Desk at: 1-888-311-7685.

Created: 4/7/2023 Page 2 of 2